Menopausal Hormone Therapy and Non-Alcoholic Fatty Liver Disease: What's the Link?
Menopausal hormone therapy (MHT) may be linked to non-alcoholic fatty liver disease (NAFLD), but research is ongoing. Learn more about the potential risks and benefits of MHT about NAFLD, and how to manage both conditions.
DR T S DIDWAL,MD
9/21/20236 min read
Unveiling the Menopausal Transition
The Role of Hormones
Before we delve into the potential link between MHT and NAFLD, it's imperative to comprehend the physiological changes that occur during menopause. Menopause, typically occurring in a woman's late 40s to early 50s, marks the cessation of menstruation and the end of reproductive years. This natural biological process is primarily characterized by a decline in the production of two key hormones: estrogen and progesterone.
Estrogen, in particular, plays a pivotal role in maintaining various bodily functions, including bone health, cardiovascular health, and the regulation of lipid metabolism. As women enter menopause, the reduction in estrogen levels can lead to a multitude of symptoms, prompting many to seek relief through hormone therapy.
The Rationale Behind Menopausal Hormone Therapy
Menopausal hormone therapy is designed to address the hormonal imbalances that occur during this transitional phase of a woman's life. It involves the administration of synthetic or bioidentical hormones to supplement the declining levels of estrogen and progesterone in the body. This therapeutic approach has been proven effective in mitigating the discomfort associated with menopause, making it a popular choice for many women.
The Enigma of Non-Alcoholic Fatty Liver Disease
Understanding NAFLD
Non-alcoholic fatty liver disease is a burgeoning health concern that has gained increasing attention in recent years. It is characterized by the accumulation of fat in the liver, not attributable to excessive alcohol consumption. NAFLD encompasses a spectrum of liver conditions, ranging from simple steatosis (fatty liver) to more severe forms, such as non-alcoholic steatohepatitis (NASH) and cirrhosis.
Exploring the Association
The potential link between menopausal hormone therapy and NAFLD has piqued the interest of researchers and healthcare professionals alike. While the exact mechanisms remain complex and multifaceted, several factors are believed to contribute to this association.
Estrogen's Influence on Lipid Metabolism
Estrogen, as a key player in lipid metabolism, has a profound impact on how the body processes and stores fats. It helps maintain a healthy balance between "good" high-density lipoprotein (HDL) cholesterol and "bad" low-density lipoprotein (LDL) cholesterol. However, during menopause, when estrogen levels plummet, this delicate balance may be disrupted.
Some studies suggest that MHT, by replenishing estrogen levels, could potentially help maintain a healthier lipid profile in postmenopausal women, reducing the risk of NAFLD development. However, the nuances of this relationship are still under investigation.
Weight Management and Hormone Therapy
Weight gain and obesity are significant risk factors for NAFLD. Menopause often brings about changes in body composition, with many women experiencing an increase in abdominal fat. This shift in fat distribution is associated with insulin resistance and an elevated risk of NAFLD.
MHT has been known to influence body composition by reducing visceral fat and promoting lean muscle mass. Consequently, it may indirectly contribute to NAFLD prevention by helping women manage their weight and metabolic health.
Individual Variability
It's essential to recognize that not all women will experience the same outcomes when it comes to MHT and NAFLD risk. Genetics, lifestyle factors, and the specific type and duration of hormone therapy can all influence the individual response.
Navigating the Research Landscape
Mixed Findings
Research on the association between menopausal hormone therapy and NAFLD is ongoing, and the findings have been somewhat mixed. While some studies suggest a potential protective effect of MHT against NAFLD, others have failed to establish a significant link. The complexity of the issue underscores the need for more extensive and nuanced investigations.
Factors to Consider
When evaluating the research on this topic, it's crucial to take into account various factors:
Duration of MHT: The length of time a woman undergoes hormone therapy may influence its impact on NAFLD risk.
Type of Hormone Therapy: Different formulations of MHT, including estrogen-only and combined estrogen-progestin therapy, may yield different outcomes.
Underlying Health Conditions: Preexisting health conditions, such as insulin resistance or metabolic syndrome, can interact with MHT and NAFLD risk.
Recent Research:
Analyzing the Impact of Menopausal Hormone Therapy (MHT) on Non-Alcoholic Fatty Liver Disease (NAFLD) by Estrogen Administration Route
A recent Scientific Reports study has delved into the intricate relationship between menopausal hormone therapy (MHT) and NAFLD, focusing on the route of estrogen administration. This groundbreaking research sheds light on how different modes of estrogen intake can affect the development and progression of NAFLD, potentially offering a ray of hope for millions of women facing this condition.
Estrogen's Protective Role
One of the intriguing aspects of NAFLD is its discrepancy in occurrence between pre-menopausal and post-menopausal women, as well as men. This disparity hints at the potential protective role of estrogen against the progression of NAFLD. Estrogen has been shown to curb fibrogenesis, inhibit stellate cell proliferation in the liver, and reduce hepatic fibrosis. Its depletion can lead to weight gain, visceral fat accumulation, and elevated triglycerides and cholesterol levels. Research has already demonstrated that MHT can lower the risk of NAFLD and the progression of liver fibrosis in patients.
The Oral vs. Transdermal Debate
Crucially, the mode of estrogen administration in MHT can play a pivotal role in its effectiveness. This study has explored the contrasting impacts of oral and transdermal MHT treatments on NAFLD over 12 months in post-menopausal women. The results are nothing short of groundbreaking.
About the Study
The study included post-menopausal women aged 45-60 who were either receiving MHT to alleviate menopausal symptoms or undergoing routine check-ups. The research spanned from January 2016 to December 2020, and the MHT regimen involved progestogen and estrogen treatment for women with a uterus, while women without a uterus received only estrogen.
The final sample comprised 368 women, segregated into two groups based on the route of estrogen administration. 75 women received transdermal MHT, while 293 opted for the oral MHT route. Menopause was defined as elevated serum follicle-stimulating hormone levels greater than 20 IU/L or at least 12 months of consecutive amenorrhea.
Key Findings
The crux of this study lies in its key findings, which have the potential to revolutionize how we approach NAFLD treatment in post-menopausal women.
Transdermal Estrogen Triumphs: The study's results suggest that transdermal estrogen might outperform its oral counterpart in preventing the development or progression of NAFLD in post-menopausal women. It achieves this by exerting an anti-steatotic effect in hepatocytes and an anti-inflammatory impact in Kupfer cells. Beyond these direct effects, estrogen also boasts beneficial impacts on lipid metabolism, which can effectively thwart the development and progression of NAFLD.
Unique Effects of Transdermal Estrogen: Compared to oral estrogen, transdermal estrogen yields distinct effects. However, it's crucial to note that, until now, no study has comprehensively compared the effects of MHT on NAFLD based on the route of estrogen administration.
Significant Reduction in NAFLD Prevalence: For the first time, this research demonstrates a significantly lower prevalence of NAFLD in the transdermal MHT group after 12 months of treatment. This substantial difference can be attributed to changes in lipid profiles after oral MHT, corroborated by negligible weight and waist circumference changes and laboratory results, such as insulin resistance.
Implications for Clinical Practice: These findings have far-reaching implications for clinical practice. Post-menopausal women with pre-existing NAFLD or a higher risk of developing it should consider transdermal MHT as a viable treatment option.
Unveiling the Impact of Estrogen Dose
This study also ventured into the uncharted territory of exploring how the dose of estrogen and the type of progestogen influence the progression of NAFLD.
Dose Matters: Surprisingly, the progression of NAFLD was found to be more prevalent with a standard dose of estrogen than with a lower dose. Fortunately, in healthy post-menopausal women, a standard dose of oral estrogen did not negatively impact the liver regarding NAFLD. Progestogen, however, can influence lipid, carbohydrate, and protein metabolism, potentially contributing to fat accumulation. The type of progestogen did not appear to significantly affect the progression of NAFLD.
Conclusion
In conclusion, this groundbreaking study presents compelling evidence in favor of transdermal MHT as a superior option for preventing the development and progression of NAFLD in post-menopausal women. These findings could guide healthcare providers in making more informed decisions about the most suitable MHT approach for their patients.
However, it's important to acknowledge the study's limitations, primarily its retrospective design, which may introduce some bias. To address this, future randomized controlled trials should be conducted to confirm the superiority of transdermal MHT. Additionally, this study did not explore the potential impacts of exercise and diet, which are recognized as preventive and therapeutic measures for
Reference:
Kim, S. E., Min, J.-S., Lee, S., Lee, D.-Y. and Choi, D. (2023) Different effects of menopausal hormone therapy on non-alcoholic fatty liver disease based on the route of estrogen administration., Nature. doi: doi.org/10.1038/s41598-023-42788-6. https://www.nature.com/articles/s41598-023-42788-6
Related Articles
